Top Markets
Coin of the day
Sunny Pharmtech Inc. Sunny Pharmtech Inc.

Sunny Pharmtech Inc.

6676
Rank in Stocks #24082
Based in Taoyuan, Taiwan, and established in 1994, Sunny Pharmtech Inc. focuses... Based in Taoyuan, Taiwan, and established in 1994, Sunny Pharmtech Inc. focuses on the entire lifecycle of pharmaceutical products, from initial research and development to manufacturing and global sales. Its operations encompass both active pharmaceutical ingredients (APIs) and finished medicinal products. The company's extensive product range includes: A lidocaine ointment, which functions as an anesthetic lubricant for intubation procedures and offers temporary relief from discomfort associated with minor burns, sunburn, skin abrasions, and insect stings. Cyanocobalamin injections, prescribed to treat vitamin B12 deficiency and pernicious anemia caused by malabsorption issues. Nitrofurantoin capsules, used in the treatment of urinary tract infections. Aminocaproic acid tablets, indicated for managing certain blood disorders and conditions involving excessive proteolytic enzyme activity. Carboprost tromethamine injections, utilized in therapeutic abortions and to address postpartum hemorrhage.
Share Price
$0.38476824
Last synced: 2026-08-21
Market Cap
$65.29M
Change (1 day)
-3.20%
Change (1 year)
-40.81%
Country
TW
Trade Sunny Pharmtech Inc. (6676)

Category

Revenue for Sunny Pharmtech Inc. (6676)
Revenue in Aug 2026 TTM: 0
According to Sunny Pharmtech Inc. latest financial reports the company's current revenue (TTM) is 0. In 2026 the company made a revenue of 0 equal to the revenue in the year 2026 that was 0. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history for Sunny Pharmtech Inc. from 2026 to 2026
Revenue at the end of each year
Year Revenue Change
Not enough data for the provided dates.
Revenue for similar companies or competitors
Company Revenue Revenue Difference Country
$12.62B -
US
$6.02B -
NL
$2.23B -
US
$15.74B -
AU
- -
CH